Abstract: A peptide and a peptide multimer according to the present invention serve to control tight bonding between cells, and thereby facilitate the absorption, through a mucous membrane, of an active ingredient of co-administered drugs and the like. Thus, the bioavailability of the active ingredient can be significantly improved, and as a result, the therapeutic effect of the active ingredient can be significantly improved.

Abstract: The present invention relates to a method for producing an interleukin-2 protein using methylotrophic yeast. The method for producing interleukin-2 according to the present invention shows high cell growth and protein synthesis rates by use of the established optimal cell line, and produces a large amount of a protein comprising interleukin-2 by use of the established optimal culture conditions utilizing methanol that is an inexpensive carbon source. In addition, the method according to the present invention isolates and purifies the protein by a simple process. Accordingly, the method according to the present invention highly pure interleukin-2, and thus has a significant effect on the mass-production of interleukin-2.

Abstract: The present disclosure relates to a method for preparing a novel sugar alcohol with a modified, that is, increased or decreased surface area and/or porosity while having flowability as a solid phase, and also to a sugar alcohol prepared by the preparing method or a pharmaceutical composition, a cosmetic composition, a food composition and a feed composition, comprising the sugar alcohol as a carrier. According to the present disclosure, the method for preparing a sugar alcohol comprises: (A) reacting the sugar alcohol in a solid state with a solvent (S), wherein the solid state sugar alcohol is not dissolved by the solvent (S) and is reacted with the solvent (S) as a solid dispersion; and (B) removing the solvent (S) therefrom. The sugar alcohol prepared by the preparing method of the present disclosure has a modified, that is, increased or decreased surface area and/or porosity in comparison with a conventional sugar alcohol.

Abstract: The present invention relates to an interleukin-2 expression construct for yeast, comprising a methanol oxidase (MOX) promoter; a human serum albumin gene or a fragment thereof; and an interleukin-2 (IL-2) gene, and to a yeast comprising the expression construct. The interleukin-2 expression construct for yeast according to the present invention makes it possible to produce an expressed and secreted fusion protein of human serum albumin (HSA) and interleukin-2 at low costs and easily separate recombinant interleukin-2 from the fusion protein. Thus, the interleukin-2 expression construct for yeast may be effectively used to produce a large amount of recombinant interleukin-2 with high purity.

Abstract: As described herein, an peptide of SEQ ID NO: 1 is modified at the terminal end. Specifically, the carboxyl-group of the leucine at the terminal end of the amino acid sequence FCIGRL (SEQ ID NO: 1) is modified with a —CONH2. This modified peptide is used as a permeation enhancer to boost the mucous membrane permeation, thereby noticeably increasing the bioavailability of a drug that is administered together with the modified peptide. The drug to be administered with the modified peptide can be cyclosporine A.

Abstract: The present invention relates to a method for producing an interleukin-2 protein using methylotrophic yeast. The method for producing interleukin-2 according to the present invention shows high cell growth and protein synthesis rates by use of the established optimal cell line, and produces a large amount of a protein comprising interleukin-2 by use of the established optimal culture conditions utilizing methanol that is an inexpensive carbon source. In addition, the method according to the present invention isolates and purifies the protein by a simple process. Accordingly, the method according to the present invention highly pure interleukin-2, and thus has a significant effect on the mass-production of interleukin-2.

Abstract: The present disclosure relates to a method for preparing a novel sugar alcohol with a modified, that is, increased or decreased surface area and/or porosity while having flowability as a solid phase, and also to a sugar alcohol prepared by the preparing method or a pharmaceutical composition, a cosmetic composition, a food composition and a feed composition, comprising the sugar alcohol as a carrier. According to the present disclosure, the method for preparing a sugar alcohol comprises: (A) reacting the sugar alcohol in a solid state with a solvent (S), wherein the solid state sugar alcohol is not dissolved by the solvent (S) and is reacted with the solvent (S) as a solid dispersion; and (B) removing the solvent (S) therefrom. The sugar alcohol prepared by the preparing method of the present disclosure has a modified, that is, increased or decreased surface area and/or porosity in comparison with a conventional sugar alcohol.

Abstract: The present invention relates to an interleukin-2 expression construct for yeast, comprising a methanol oxidase (MOX) promoter; a human serum albumin gene or a fragment thereof; and an interleukin-2 (IL-2) gene, and to a yeast comprising the expression construct. The interleukin-2 expression construct for yeast according to the present invention makes it possible to produce an expressed and secreted fusion protein of human serum albumin (HSA) and interleukin-2 at low costs and easily separate recombinant interleukin-2 from the fusion protein. Thus, the interleukin-2 expression construct for yeast may be effectively used to produce a large amount of recombinant interleukin-2 with high purity.

Abstract: The present invention provides a preparation method for agomelatine-resorcinol and agomelatine-hydroquinone co-crystals using the solvent-antisolvent method that enables a commercial mass production. The co-crystals prepared by the preparation method of the present invention displays high dissolution rate and high stability in acidic-to-neutral media.

Abstract: The present invention modifies the carboxyl-terminal end of a peptide used as a permeation enhancer to enhance the function of the peptide to boost the mucous membrane permeation, thereby noticeably increasing the bioavailability of a drug that is administered together with the peptide.

Abstract: The present invention provides a preparation method for agomelatine-resorcinol and agomelatine-hydroquinone co-crystals using the solvent-antisolvent method that enables a commercial mass production. The co-crystals prepared by the preparation method of the present invention displays high dissolution rate and high stability in acidic-to-neutral media.

Abstract: The invention relates to a therapeutic composition comprising a therapeutically effective amount of one or more therapeutic agents and a nasal mucosa absorption-enhancing amount of one or more tight junction agonists. The invention further relates to a method of treating a subject comprising intranasally administering the composition of the invention to the subject.

Abstract: The present invention provides compositions and methods for the administration of the compositions to mammals. The compositions comprise therapeutic agents and an intestinal absorption enhancing amount of one or more tight junction agonists. Tight junction agonists include zonulin and/or ZOT receptor agonists. Methods of the invention include orally administering compositions of the invention.